DURECT Corporation Presenting at the Rodman & Renshaw Healthcare Conference

Download PDF:

CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw
Techvest Global Healthcare Conference at 3:30 PM local time (10:30 AM, Eastern
Daylight Time) on Wednesday, May 12, 2004 in London, England. Presenting for
the company will be Thomas A. Schreck, Chief Financial Officer for DURECT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

There will be a live webcast of the presentation from the Conference. The
webcast will be available on DURECT’s website under the “Investor Relations”
section. The presentation will also be available for replay on DURECT’s
website for a period of up to 7 days after the conference.

About DURECT Corporation

DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical
products. DURECT’s goal is to deliver the right drug to the right site in the
right amount at the right time. DURECT’s lead product in development is
CHRONOGESIC(R), a 3-month product for the treatment of chronic pain. DURECT
also owns three proprietary drug delivery platform technologies, including the
SABER(TM) Delivery System (a patented and versatile depot injectable useful
for protein and small molecule delivery), the MICRODUR(TM) Biodegradable
Microparticulates (microspheres injectable system) and the DURIN(TM)
Biodegradable Implant (drug-loaded implant system) upon which DURECT is
developing a pipeline of other products.

trademarks of DURECT Corporation.

The statements in this press release regarding DURECT’s products in
development, product development plans, clinical trials and projected
financial results are forward-looking statements involving risks and
uncertainties that can cause actual results to differ materially from those in
such forward-looking statements. Potential risks and uncertainties include,
but are not limited to, DURECT’s ability to complete the design, development,
and manufacturing process development of its products, manufacture and
commercialize its products, obtain product and manufacturing approvals from
regulatory agencies, manage its growth and expenses, manage relationships with
third parties, finance its activities and operations, as well as marketplace
acceptance of DURECT’s products. Further information regarding these and other
risks is included in DURECT’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2003 filed with the SEC on March 11, 2004, DURECT’s
Quarterly Report on Form 10Q and other periodic reports filed with the SEC
under the heading “Factors that may affect future results.”

CHRONOGESIC, our post operative pain product and other products mentioned
above are under development and have not been submitted or approved for
commercialization by the US Food and Drug Administration or other health


/CONTACT: Schond L. Greenway, Executive Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
/Web site: http://www.www.durect.com /

Scroll to Top